BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics and research collaborators from the University of Michigan will present new preclinical data supporting Stoke’s development of its antisense oligonucleotide technology to treat Dravet Syndrome at the annual meeting of the American Epilepsy Society in New Orleans.
Lori Isom, Ph.D., Maurice H. Seevers professor and chair of pharmacology at University of Michigan Medical School, will present the data at two poster sessions and one platform presentation, which will include a Q&A. Stoke’s executive team will also attend the conference.
- Poster Session 1: Dec. 1, 2018, 12 - 6 p.m. CST in Convention Center Hall H, First Floor.
- Investigators Workshop Poster Session: Dec. 2, 2018 from 12-1:30p.m. CST in Convention Center Room 288.
- Platform Session C.02: Dec. 3 at 3:30p.m. CST in Convention Center Room 295.
The new data demonstrate the ways in which Stoke’s Targeted Augmentation of Nuclear Gene Output (TANGO) technology upregulates the Scn1a gene and restores physiologic levels of the NaV1.1 sodium ion channel protein to treat Dravet Syndrome, a rare and devastating form of epilepsy.
About Stoke Therapeutics
Launched in 2018, Stoke
Therapeutics is a biotechnology company working to increase gene
expression to treat a wide array of severe genetic diseases, including
genetic conditions affecting the central nervous system, eye, liver and
kidney. Stoke has raised $130 million in funding from two rounds of
financing; investors include RTW Investments, RA Capital Management,
Cormorant Asset Management, Perceptive Advisors, funds managed by Janus
Henderson Investors, Redmile Group, Sphera Funds Management, and
Alexandria Venture Investments, as well as founding investor Apple Tree
Partners. For more information, visit www.stoketherapeutics.com and
follow Stoke on Twitter @StokeTx.
